Randomised controlled study of iron supplementation to support the response to recombinant human erythropoietin for the treatment of chemotherapy-induced anaemia
| ISRCTN | ISRCTN11830961 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11830961 |
| ClinicalTrials.gov number | NCT00482716 |
| Secondary identifying numbers | Version 2 (Oct 2006) |
- Submission date
- 17/11/2006
- Registration date
- 04/05/2007
- Last edited
- 07/08/2009
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Samir Agrawal
Scientific
Scientific
Barts and the London NHS Trust
St Bartholomews Hospital
West Smithfield
London
EC1A 7BE
United Kingdom
| Phone | +44 (0)20 7601 2331 |
|---|---|
| s.g.agrawal@qmul.ac.uk |
Study information
| Study design | Randomised, controlled, open label, prospective trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | |
| Study acronym | High Iron Study |
| Study objectives | Parental iron will optimise the response to recombinant erythropoietin therapy in patients who are iron replete. |
| Ethics approval(s) | Approval received from the East London and the City Research Ethics Committee on the 17th October 2006 (ref: 06/Q0605/93). |
| Health condition(s) or problem(s) studied | Chemotherapy induced anaemia |
| Intervention | As of 07/08/2009 the status of this record was updated to read: 'STOPPED', as this trial terminated early due to poor patient recruitment. The initial anticipated end date was 01/11/2007 but this was extended after the lack of recruitment. Eighty patients will be treated and randomised to receive either epoietin or epoietin plus 200 mg intravenous iron sucrose (Venefor) weekly for ten weeks or until a haemoglobin (Hb) of 13 g/dl is achieved (whichever is first). Any patient requiring blood transfusion while on the study will be considered to have completed the study at the time of the transfusion. Patients will be followed until the Hb reaches 13 g or until the end of the study period. Haemoglobin levels will be measured weekly. Other blood tests include: Baseline: zinc protoporphyrin (ZPP), reticulocyte haemoglobin content (CHR), transferrin saturation (TSAT), full blood count (FBC), ferritin, reticulocytes (Retic), vitamin B12, red cell folate, soluble transferrin receptor (sTFR), serum erythropoietin (EPO) Week one: FBC, CHR, retic Week four, eight and 12: as per baseline (without B12 and red cell folate) |
| Intervention type | Supplement |
| Primary outcome measure | The primary outcome will be the maximum haemoglobin achieved during the conduct of the study. |
| Secondary outcome measures | The secondary outcome will be the time to zenith haemoglobin or the achievement of a haemoglobin level of more than 13 g. All side effects will be recorded and graded although none are anticipated. A further stratification will be responsive, stable or progressive disease. |
| Overall study start date | 01/11/2006 |
| Completion date | 24/04/2009 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | Eighty patients |
| Key inclusion criteria | 1. Any patients with a haemoglobin of less than or equal to 10.5 g/dl who is going to receive at least six more weeks of chemotherapy for any non-myeloid malignancy 2. Any patients with a percent saturation of transferrin more than or equal to 20% and a serum ferritin between 225 and 2250 pmol/L. Confirmatory data will include a reticulocyte haemoglobin content (CHR) more than 31 and zinc protoporphyrin (ZPP) less than 80 3. Patients must be able to understand and signed written informed consent 4. An Eastern Cooperative Oncology Group (ECOG) performance status of zero to two |
| Key exclusion criteria | 1. Patients with an anaemia of origin other than cancer or cancer chemotherapy 2. Prior intravenous (IV) iron therapy 3. Expectation of actual transfusion requirement during the course of the study. A transfusion given after randomisation wil be a study endpoint for that patient. 4. Allergy or intolerance to recombinant erythropoietin 5. Uncontrolled hypertension 6. Active infection 7. Primary bone marrow malignancies except for multiple myeloma, chronic lymphocytic leukaemia and indolent non Hogkin's lymphoma, where erythropoiesis-stimulating agents (ESA) therapy has been proven to be beneficial |
| Date of first enrolment | 01/11/2006 |
| Date of final enrolment | 24/04/2009 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Barts and the London NHS Trust
London
EC1A 7BE
United Kingdom
EC1A 7BE
United Kingdom
Sponsor information
Barts and the London NHS Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Research and Development Department
3rd Floor Rutland House
42-46 New Road
Whitechapel
London
E1 2AX
England
United Kingdom
| Phone | +44 (0)20 7882 7260 |
|---|---|
| Gerry.Leonard@bartsandthelondon.nhs.uk | |
| Website | http://www.bartsandthelondon.org.uk/ |
"ROR" |
https://ror.org/00b31g692 |
Funders
Funder type
Hospital/treatment centre
St. Bartholomew's Hospital (UK) - internal funding
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
